Table 3.
Summary of previous studies for the investigation of the efficacy of first-line eradication therapy between clarithromycin-sensitive and -resistant strains.
| First author [ref. no.] | Year | Method | Clarithromycin-resistance | VPZ-containing eradication regimen |
PPI-containing eradication regimen |
||||
|---|---|---|---|---|---|---|---|---|---|
| Number | Regimen | Eradication rate | Number | Regimen | Eradication rate | ||||
| Murakami (Murakami et al., 2016) | 2016 | RCT | Sensitive | 205 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
97.6% | 185 | LPZ: 30 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
97.3% |
| Resistant | 100 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
82.0% | 115 | LPZ: 30 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
40.0% | |||
| Noda (Noda et al., 2016) | 2016 | RST | Sensitive | 44 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 400 mg bid |
100% | 25 | OPZ: 20 mg bid, LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
88.0% |
| Resistant | 32 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 400 mg bid |
87.5% | 13 | OPZ: 20 mg bid, LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
53.8% | |||
| Matsumoto (Matsumoto et al., 2016) | 2016 | RST | Sensitive | 57 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 mg bid |
100% | 212 | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
87.8% |
| Resistant | 46 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 mg bid |
76.1% | 97 | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
40.2% | |||
| Sugimoto (Sugimoto et al., 2017) | 2017 | OS | Sensitive | 19 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 mg bid |
89.5% | |||
| Resistant | 14 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 mg bid |
78.6% | ||||||
| Sue (Sue et al., 2017a) | 2017 | RST | Sensitive | 180 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
88.9% | |||
| Resistant | 56 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
73.2% | ||||||
| Sue (Sue et al., 2018a) | 2018 | RCT | Sensitive | 55 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
87.3% | 51∗ | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
76.5% |
| Resistant | 41 | VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid |
82.9% | ||||||
All paper to investigate efficacy of first-line vonoprazan-containing eradication therapy investigated susceptibility to antimicrobial agents up until September 2018 were listed. AMX, amoxicillin; bid, twice daily dosing; CLR, clarithromycin; EPZ, esomeprazole; ITT, intention to treat analysis; LPZ, lansoprazole; MNZ, metronidazole; OPZ, omeprazole; PP, per protocol analysis; PPI, proton pump inhibitor; OS, observational study; RCT, randomized control trial; RST, retrospective cohort trial; RPZ, rabeprazole; VPZ, vonoprazan.